CTRV stock forecast
Our latest prediction for ContraVir Pharmaceuticals, Inc.'s stock price was made on the June 20, 2017 when the stock price was at 5.14$.
In the short term (2weeks), CTRV's stock price should outperform the market by 2.71%. During that period the price should oscillate between -10.90% and +16.43%.
In the medium term (3months), CTRV's stock price should outperform the market by 2.41%. During that period the price should oscillate between -23.47% and +39.18%.Get email alerts
Create a solid portfolio with CTRV
About ContraVir Pharmaceuticals, Inc.
ContraVir Pharmaceuticals, Inc. engages in the development and commercialization of pleiotropic drug therapy for the treatment of chronic liver disease. It focuses on the development of its product candidate CRV431, a cyclophilin inhibitor that targets biochemical pathways involved in the progression of liver disease. The company was founded on May 15, 2013 and is headquartered in Edison, NJ.
At the moment the company doesn't generate any revenue.
On its last earning announcement, the company reported a loss of -2.00$ per share.
The book value per share is -0.11$
Three months stock forecastJune 20, 2017
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|